These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32890415)

  • 21. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
    Bramlage P; Swift SL; Thoenes M; Minguet J; Ferrero C; Schmieder RE
    Eur J Heart Fail; 2016 Jan; 18(1):28-37. PubMed ID: 26634965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
    Salukhov VV; Shamkhalova MS; Duganova AV
    Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
    Amazit L; Le Billan F; Kolkhof P; Lamribet K; Viengchareun S; Fay MR; Khan JA; Hillisch A; Lombès M; Rafestin-Oblin ME; Fagart J
    J Biol Chem; 2015 Sep; 290(36):21876-89. PubMed ID: 26203193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dehydrogenative [2 + 2 + 2] Cycloaddition of Cyano-yne-allene Substrates: Convenient Access to 2,6-Naphthyridine Scaffolds.
    Haraburda E; Lledó A; Roglans A; Pla-Quintana A
    Org Lett; 2015 Jun; 17(12):2882-5. PubMed ID: 26068506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
    Raj R
    Curr Opin Nephrol Hypertens; 2022 May; 31(3):265-271. PubMed ID: 35165249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mineralocorticoid Receptor Antagonism by Finerenone Attenuates Established Pulmonary Hypertension in Rats.
    Tu L; Thuillet R; Perrot J; Ottaviani M; Ponsardin E; Kolkhof P; Humbert M; Viengchareun S; Lombès M; Guignabert C
    Hypertension; 2022 Oct; 79(10):2262-2273. PubMed ID: 35979822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic kinetic resolution based asymmetric transfer hydrogenation of α-alkoxy-β-ketophosphonates. Diastereo- and enantioselective synthesis of monoprotected 1,2-dihydroxyphosphonates.
    Son SM; Lee HK
    J Org Chem; 2014 Mar; 79(6):2666-81. PubMed ID: 24568588
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?
    Doggrell SA
    Expert Opin Pharmacother; 2021 Jul; 22(10):1253-1256. PubMed ID: 33764251
    [No Abstract]   [Full Text] [Related]  

  • 30. Investigating the use of finerenone in children with chronic kidney disease and proteinuria: design of the FIONA and open-label extension studies.
    Schaefer F; Montini G; Kang HG; Walle JV; Zaritsky J; Schreuder MF; Litwin M; Scalise A; Scott H; Potts J; Iveli P; Breitenstein S; Warady BA
    Trials; 2024 Mar; 25(1):203. PubMed ID: 38509517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
    Li P; Cui Y; Xu X; Dong J; Liao L
    Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A fluorescence chemo sensor approach for determination of finerenone in pharmaceutical formulation and human plasma: Method development and validation.
    Alsharif ST; Alaqel SL; Almalki AH; Algarni MA; Alnemari RM; H Abduljabbar M; Abdelazim AH
    Spectrochim Acta A Mol Biomol Spectrosc; 2024 Mar; 309():123836. PubMed ID: 38181624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asymmetric Transfer Hydrogenation of 2,3-Disubstituted Flavanones through Dynamic Kinetic Resolution Enabled by Retro-Oxa-Michael Addition: Construction of Three Contiguous Stereogenic Centers.
    Xie QX; Liu LX; Zhu ZH; Yu CB; Zhou YG
    J Org Chem; 2022 Jun; 87(11):7521-7530. PubMed ID: 35605190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances.
    Chen X; Li X; Zhang K; Lian K; Zhang W; Song Y; Kan C; Zhang J; Han F; Sun X; Guo Z
    Clin Exp Nephrol; 2024 Feb; 28(2):125-135. PubMed ID: 37847437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enantiodivergent Atroposelective Synthesis of Chiral Biaryls by Asymmetric Transfer Hydrogenation: Chiral Phosphoric Acid Catalyzed Dynamic Kinetic Resolution.
    Mori K; Itakura T; Akiyama T
    Angew Chem Int Ed Engl; 2016 Sep; 55(38):11642-6. PubMed ID: 27491630
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renin-angiotensin system blockade: Finerenone.
    Ruilope LM; Tamargo J
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S47-S53. PubMed ID: 28577743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finerenone: First Approval.
    Frampton JE
    Drugs; 2021 Oct; 81(15):1787-1794. PubMed ID: 34519996
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly Enantioselective Synthesis of Pharmaceuticals at Chiral-Encoded Metal Surfaces.
    Somsri S; Suwankaisorn B; Yomthong K; Srisuwanno W; Klinyod S; Kuhn A; Wattanakit C
    Chemistry; 2023 Nov; 29(61):e202302054. PubMed ID: 37555292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diastereo- and enantioselective anti-selective hydrogenation of α-amino-β-keto ester hydrochlorides and related compounds using transition-metal-chiral-bisphosphine catalysts.
    Hamada Y
    Chem Rec; 2014 Apr; 14(2):235-50. PubMed ID: 24550034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.